Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Acquired by Swiss National Bank

Posted by Defense World Staff on May 17th, 2023

Swiss National Bank raised its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) by 2.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 166,054 shares of the medical equipment provider’s stock after purchasing an additional 3,300 shares during the period. Swiss National Bank owned 0.24% of Lantheus worth $8,462,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of LNTH. CWM LLC increased its position in Lantheus by 82.1% during the third quarter. CWM LLC now owns 366 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 165 shares during the last quarter. Wipfli Financial Advisors LLC acquired a new position in Lantheus during the third quarter worth approximately $30,000. Wolverine Asset Management LLC acquired a new position in Lantheus during the fourth quarter worth approximately $36,000. Shell Asset Management Co. acquired a new position in Lantheus during the fourth quarter worth approximately $80,000. Finally, Quadrant Capital Group LLC increased its position in Lantheus by 435.6% during the third quarter. Quadrant Capital Group LLC now owns 1,473 shares of the medical equipment provider’s stock worth $104,000 after purchasing an additional 1,198 shares during the last quarter. Institutional investors and hedge funds own 97.62% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. SVB Securities boosted their price objective on shares of Lantheus from $120.00 to $127.00 in a research note on Friday, May 5th. JMP Securities boosted their price objective on shares of Lantheus from $120.00 to $130.00 in a research note on Friday, May 5th. Truist Financial boosted their price objective on shares of Lantheus from $115.00 to $125.00 in a research note on Friday, May 5th. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday, May 11th. Finally, Mizuho upped their target price on shares of Lantheus from $115.00 to $125.00 in a research note on Friday, May 5th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $121.83.

Lantheus Stock Down 1.8 %

Shares of NASDAQ:LNTH opened at $97.43 on Wednesday. The stock has a market capitalization of $6.66 billion, a price-to-earnings ratio of -314.29 and a beta of 0.66. Lantheus Holdings, Inc. has a 1-year low of $47.46 and a 1-year high of $100.85. The company’s fifty day moving average is $85.19 and its two-hundred day moving average is $67.45. The company has a debt-to-equity ratio of 1.25, a quick ratio of 2.65 and a current ratio of 2.80.

Lantheus (NASDAQ:LNTH – Get Rating) last issued its earnings results on Thursday, May 4th. The medical equipment provider reported $1.37 earnings per share for the quarter, topping analysts’ consensus estimates of $1.21 by $0.16. The company had revenue of $300.78 million for the quarter, compared to analysts’ expectations of $280.65 million. Lantheus had a negative net margin of 1.72% and a positive return on equity of 58.60%. Equities analysts anticipate that Lantheus Holdings, Inc. will post 4.65 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Mary Anne Heino sold 82,055 shares of the stock in a transaction dated Friday, March 3rd. The shares were sold at an average price of $73.00, for a total value of $5,990,015.00. Following the sale, the chief executive officer now owns 741,650 shares of the company’s stock, valued at approximately $54,140,450. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CFO Robert J. Jr. Marshall sold 20,587 shares of the stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $72.56, for a total value of $1,493,792.72. Following the sale, the chief financial officer now owns 138,152 shares of the company’s stock, valued at approximately $10,024,309.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Mary Anne Heino sold 82,055 shares of the stock in a transaction dated Friday, March 3rd. The stock was sold at an average price of $73.00, for a total transaction of $5,990,015.00. Following the completion of the sale, the chief executive officer now directly owns 741,650 shares in the company, valued at approximately $54,140,450. The disclosure for this sale can be found here. Over the last three months, insiders have sold 242,018 shares of company stock valued at $18,461,067. Company insiders own 1.50% of the company’s stock.

About Lantheus

(Get Rating)

Lantheus Holdings, Inc engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments.

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.